

RECEIVED  
CENTRAL FAX CENTER  
JUL 28 2005

CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below. FAX: 571-273-8300	
<u>LAURA WALTZ</u> Type or print name of person signing certification	
<u>Laura Waltz</u> Signature	<u>7/28/05</u> Date

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: ALLEN Douglas J

Serial No.: 10/613619

Application Date: July 3, 2003

US Nat'l Entry  
Date (if applicable):

For: 2-METHYL-THIENO-BENZODIAZEPINE FORMULATION

Docket No.: X11666C

Group Art Unit: 1618

Examiner:  
SPEAR, JAMES M

Conf No.: 4376

**TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**Identification of Person Making This Disclaimer**

I, Nelsen L. Lentz, am employed by Eli Lilly and Company, and I am an attorney of record in the above-identified patent application. In that capacity, I am authorized to sign this disclaimer on behalf of Eli Lilly and Company.

**Identity of Assignee**

I hereby verify that the assignee owning all of the interest in this application is:

Eli Lilly and Company  
Lilly Corporate Center  
Indianapolis, Indiana 46285

**Recordal of Assignment in PTO**

The assignment was recorded on May 8, 2000, Reel 10801, Frame 0715.

07/29/2005 HLE333 00000004 050840 10613619

02 FC:1814 130.00 DA

Serial No. 10/613619

**Extent of Interest**

The extent of Eli Lilly and Company's interest is in the whole of this invention.

**Disclaimer**

I hereby disclaim the terminal part of any patent granted on this application, which would extend beyond the expiration date of:

United States Patent No. 6,617,321 B2 and hereby agree that any patent granted on this application shall be enforceable only for and during such period that the legal title to the patent shall be the same as the legal title to United States Patent No. 6,617,321 B2.

I do not disclaim any terminal part of any patent granted on this application prior to the expiration date of the full statutory term of United States Patent No. 6,617,321 B2 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its full statutory term other than as presently shortened by any terminal disclaimer.

**Fee Payment**

Please charge \$110.00, the fee set forth in 37 C.F.R. 1.20(d), and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840 in the name of Eli Lilly and Company. Two copies of this disclaimer are enclosed.

ELI LILLY AND COMPANY

By: 

Nelsen L. Lentz

Attorney/Agent for Applicant(s)

Registration No. 38,537

Phone: 317-276-1207